New drug ravulizumab aims to control rare blood disorder aHUS

NCT ID NCT07308574

Recruiting now Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing the drug ravulizumab in 20 people with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. The goal is to see if the drug improves platelet counts and kidney function over 26 weeks. All participants receive the drug, and researchers will monitor safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab
What this could lead to: If successful, this study could confirm ravulizumab as a reliable treatment to control aHUS and prevent kidney damage.
What could go wrong: This is a small, single-arm study with no placebo group, so results may not be definitive. Ravulizumab also carries risks like increased susceptibility to infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AHUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical hemolytic-uremic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AHUS ATYPICAL HEMOLYTIC UREMIC SYNDROME

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Bunkyō City, 113-8655, Japan
Research Site
NOT_YET_RECRUITING

Hirakata-shi, 573-1191, Japan
Research Site
RECRUITING

Iruma-Gun, 350-0495, Japan
Research Site
NOT_YET_RECRUITING

Kyoto, 602-8566, Japan
Research Site
NOT_YET_RECRUITING

Matsumoto-shi, 390-8621, Japan
Research Site
NOT_YET_RECRUITING

Miyazaki, 889-1692, Japan
Research Site
RECRUITING

Nagoya, 466-8650, Japan
Research Site
NOT_YET_RECRUITING

Nara, 630-8581, Japan
Research Site
NOT_YET_RECRUITING

Nerima-ku, 177-8521, Japan
Research Site
NOT_YET_RECRUITING

Sapporo, 060-8638, Japan
Research Site
NOT_YET_RECRUITING

Shinjuku-ku, 162-8666, Japan
Research Site
RECRUITING

Tsu, 514-8507, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.